PTPN11 and acute myeloid leukemia: Acute leukemias with larger patient populations, such as AML and B-cell acute lymphoblastic leukemia, have SHP2 mutation rates between 5 and 10%, and those mutations are associated with poor clinical outcomes as well as resistance to targeted therapies (47, 48).